In a 45-year-old woman with a history of hypomania and alcohol use disorder, what laboratory evaluations and treatment plan are recommended?

Laboratory Evaluation and Treatment for 45-Year-Old Female with Hypomania and Alcoholism

Screen immediately with AUDIT (Alcohol Use Disorders Identification Test) to quantify alcohol use severity, then obtain CBC, comprehensive metabolic panel with liver transaminases (AST, ALT, GGT), and consider direct biomarkers (urine EtG, blood PEth) to objectively assess recent alcohol consumption. 1, 2

Laboratory Workup

Initial Screening and Assessment

• Use AUDIT for alcohol screening - this is the most effective validated tool for detecting alcohol use disorder in clinical settings 1
• Direct biomarkers provide objective evidence of recent use:
  • Urine EtG (ethyl glucuronide): 76-89% sensitivity, detects use up to 3 days 3
  • Blood PEth (phosphatidylethanol): 97-100% sensitivity, detects use for 2-3 weeks 3
  • These are superior to indirect markers like CDT which have lower sensitivity (21-50%) 3

Essential Laboratory Tests

• Complete blood count - assess for macrocytosis, thrombocytopenia
• Liver function tests - AST, ALT, GGT (gamma-glutamyl transpeptidase is most sensitive for alcohol-related liver injury) 2
• Comprehensive metabolic panel - assess renal function (critical for medication selection), electrolytes
• Consider thyroid function - can mimic or exacerbate mood symptoms

Mental Health Assessment

• Screen for bipolar disorder severity using validated tools, as hypomania suggests bipolar spectrum disorder
• Use K10 or K6 (Kessler Psychological Distress Scale) to screen for comorbid mental disorders 1
• Assess for concurrent substance use - tobacco, other drugs 1

Treatment Approach

Alcohol Use Disorder Management

For this patient with comorbid hypomania and alcohol use disorder, initiate acamprosate 666 mg three times daily as first-line pharmacotherapy, combined with cognitive behavioral therapy. 3, 4

Pharmacotherapy Selection - Critical Decision Points

Acamprosate is the optimal choice for several reasons:

• No hepatic metabolism - excreted renally, avoiding hepatotoxicity concerns 3
• No reported hepatotoxicity unlike naltrexone and disulfiram 3
• Effective for maintaining abstinence (Level A evidence) 1
• Safe in patients with mood disorders - does not interact with mood stabilizers

Avoid these medications in this patient:

• Disulfiram - contraindicated due to hepatotoxicity risk and not recommended in alcohol-associated liver disease 3
• Naltrexone - undergoes hepatic metabolism, hepatotoxicity concerns, not studied in patients with liver disease 3
• Baclofen - while studied in cirrhosis, can impair mentation and may worsen mood symptoms 3

Psychosocial Interventions

Combine medication with cognitive behavioral therapy (CBT) - this combination is superior to either alone:

• CBT plus pharmacotherapy shows enhanced clinical benefit compared to pharmacotherapy alone 4
• Motivational interviewing is effective for patients ambivalent about alcohol cessation 3
• Integrate alcohol treatment with medical/psychiatric care - this is the best option for managing comorbid conditions 3

Bipolar Disorder (Hypomania) Management

Critical consideration: Alcohol use predicts worsening mood symptoms and reduced workplace functioning in bipolar disorder 5

• Recent evidence shows alcohol use is associated with worse depressive symptoms (β = 0.04) and manic/hypomanic symptoms (β = 0.04) over subsequent 6 months 5
• Alcohol abstinence is the optimal outcome for patients with alcohol dependence and comorbid psychiatric conditions 1
• More intensive interventions are needed for comorbid conditions as this population has worse prognosis 1

Coordinate treatment for both disorders simultaneously:

• Mood stabilizers should be initiated/optimized by psychiatry
• Avoid medications that worsen either condition - be cautious with benzodiazepines given addiction risk
• Monitor closely as alcohol use directly impacts mood stability 5

Monitoring and Follow-up

• Weekly visits initially for medication titration and monitoring
• Repeat liver function tests at 4-8 weeks
• Assess treatment response using standardized measures (drinks per drinking day, heavy drinking days)
• Screen for relapse - return to problematic drinking is common; maintain harm-reduction approach if abstinence not achieved 1

Common Pitfalls to Avoid

1. Do not delay treatment waiting for "motivation" - pharmacotherapy works even in non-treatment-seeking patients
2. Do not treat only one condition - integrated treatment of both AUD and bipolar disorder is essential 1
3. Do not use naltrexone as first-line in this patient given hepatotoxicity concerns and lack of data in liver disease 3
4. Do not assume mood symptoms will resolve with sobriety alone - both require active treatment 5